Lenz Therapeutics has received approval from the Food and Drug Administration for Vizz (aceclidine ophthalmic solution) 1.44% ...

It is anticipated that Vizz, manufactured by Lenz Therapeutics, will become commercially available in the US by the end of ...

Vizz being approved by the FDA marks a step in the right direction for treating vision loss in an accessible way.

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

On Thursday, LENZ Therapeutics LENZ earned a positive adjustment to its Relative Strength (RS) Rating, from 89 to 92. Please watch the video at Investors.com - Find Top Growth Stocks With The IBD ...

LENZ Therapeutics ( (LENZ) ) has shared an announcement. On July 31, 2025, LENZ Therapeutics announced the FDA approval of VIZZ, an aceclidine-based eye drop for treating presbyopia in adults, ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States ...

LENZ Therapeutics announced that FDA approved Presbyopia treatment Vizz making it the first and only aceclidine-based eye drop to be granted approval by the FDA, with samples estimated to reach the ...

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.

About LENZ Therapeutics LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve ...